AI assistant
Editas Medicine, Inc. — Director's Dealing 2016
Feb 3, 2016
33260_dirs_2016-02-02_c96982a9-97a4-4ba4-bd63-424daf590377.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2016-02-02
Reporting Person: Flagship Ventures Fund IV, L.P. (10% Owner)
Reporting Person: Flagship Ventures Fund IV-Rx, L.P. (10% Owner)
Reporting Person: Flagship Ventures Fund IV General Partner LLC (10% Owner)
Reporting Person: AFEYAN NOUBAR (10% Owner)
Reporting Person: KANIA EDWIN M JR (10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A-1 Preferred Stock | $ | Common Stock (2039549) | Direct | ||
| Series A-1 Preferred Stock | $ | Common Stock (509885) | Indirect | ||
| Series A-2 Preferred Stock | $ | Common Stock (1617015) | Direct | ||
| Series A-2 Preferred Stock | $ | Common Stock (404253) | Indirect | ||
| Series B Preferred Stock | $ | Common Stock (307692) | Direct | ||
| Series B Preferred Stock | $ | Common Stock (76922) | Indirect |
Footnotes
F1: The Series A-1 Preferred Stock is convertible into Common Stock on a 2.6-for-one basis into the number of shares shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
F2: Held by Flagship Ventures Fund IV, L.P. ("Flagship IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons other than Flagship IV disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
F3: Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons other than Flagship IV-Rx disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
F4: The Series A-2 Preferred Stock is convertible into Common Stock on a 2.6-for-one basis into the number of shares shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
F5: The Series B Preferred Stock is convertible into Common Stock on a 2.6-for-one basis into the number of shares shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.